Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.

Kauko O, O'Connor CM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S, Yetukuri L, Yadav B, Padzik A, Laajala TD, Haapaniemi P, Momeny M, Varila T, Ohlmeyer M, Aittokallio T, Wennerberg K, Narla G, Westermarck J.

Sci Transl Med. 2018 Jul 18;10(450). pii: eaaq1093. doi: 10.1126/scitranslmed.aaq1093.

PMID:
30021885
2.

Drug sensitivity screening and genomic characterization of 45 HPV-negative head and neck carcinoma cell lines for novel biomarkers of drug efficacy.

Lepikhova T, Karhemo PR, Louhimo R, Yadav B, Murumägi A, Kulesskiy E, Kivento M, Sihto H, Grénman R, Syrjänen SM, Kallioniemi O, Aittokallio T, Wennerberg K, Joensuu H, Monni O.

Mol Cancer Ther. 2018 Jul 3. pii: molcanther.0733.2017. doi: 10.1158/1535-7163.MCT-17-0733. [Epub ahead of print]

PMID:
29970484
3.

Methods for High-throughput Drug Combination Screening and Synergy Scoring.

He L, Kulesskiy E, Saarela J, Turunen L, Wennerberg K, Aittokallio T, Tang J.

Methods Mol Biol. 2018;1711:351-398. doi: 10.1007/978-1-4939-7493-1_17.

PMID:
29344898
4.

Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins.

Bulanova D, Ianevski A, Bugai A, Akimov Y, Kuivanen S, Paavilainen H, Kakkola L, Nandania J, Turunen L, Ohman T, Ala-Hongisto H, Pesonen HM, Kuisma MS, Honkimaa A, Walton EL, Oksenych V, Lorey MB, Guschin D, Shim J, Kim J, Than TT, Chang SY, Hukkanen V, Kulesskiy E, Marjomaki VS, Julkunen I, Nyman TA, Matikainen S, Saarela JS, Sane F, Hober D, Gabriel G, De Brabander JK, Martikainen M, Windisch MP, Min JY, Bruzzone R, Aittokallio T, Vähä-Koskela M, Vapalahti O, Pulk A, Velagapudi V, Kainov DE.

Viruses. 2017 Sep 25;9(10). pii: E271. doi: 10.3390/v9100271.

5.

Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells.

Haltia UM, Andersson N, Yadav B, Färkkilä A, Kulesskiy E, Kankainen M, Tang J, Bützow R, Riska A, Leminen A, Heikinheimo M, Kallioniemi O, Unkila-Kallio L, Wennerberg K, Aittokallio T, Anttonen M.

Gynecol Oncol. 2017 Mar;144(3):621-630. doi: 10.1016/j.ygyno.2016.12.016. Epub 2017 Jan 16.

PMID:
28104295
6.

HB-GAM (pleiotrophin) reverses inhibition of neural regeneration by the CNS extracellular matrix.

Paveliev M, Fenrich KK, Kislin M, Kuja-Panula J, Kulesskiy E, Varjosalo M, Kajander T, Mugantseva E, Ahonen-Bishopp A, Khiroug L, Kulesskaya N, Rougon G, Rauvala H.

Sci Rep. 2016 Sep 27;6:33916. doi: 10.1038/srep33916.

7.

HMGB4 is expressed by neuronal cells and affects the expression of genes involved in neural differentiation.

Rouhiainen A, Zhao X, Vanttola P, Qian K, Kulesskiy E, Kuja-Panula J, Gransalke K, Grönholm M, Unni E, Meistrich M, Tian L, Auvinen P, Rauvala H.

Sci Rep. 2016 Sep 9;6:32960. doi: 10.1038/srep32960.

8.

Phosphoproteomics to Characterize Host Response During Influenza A Virus Infection of Human Macrophages.

Söderholm S, Kainov DE, Öhman T, Denisova OV, Schepens B, Kulesskiy E, Imanishi SY, Corthals G, Hintsanen P, Aittokallio T, Saelens X, Matikainen S, Nyman TA.

Mol Cell Proteomics. 2016 Oct;15(10):3203-3219. Epub 2016 Aug 2.

9.

Precision Cancer Medicine in the Acoustic Dispensing Era: Ex Vivo Primary Cell Drug Sensitivity Testing.

Kulesskiy E, Saarela J, Turunen L, Wennerberg K.

J Lab Autom. 2016 Feb;21(1):27-36. doi: 10.1177/2211068215618869. Epub 2015 Dec 2.

PMID:
26721820
10.

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies.

Yadav B, Pemovska T, Szwajda A, Kulesskiy E, Kontro M, Karjalainen R, Majumder MM, Malani D, Murumägi A, Knowles J, Porkka K, Heckman C, Kallioniemi O, Wennerberg K, Aittokallio T.

Sci Rep. 2014 Jun 5;4:5193. doi: 10.1038/srep05193.

11.

Antifungal application of nonantifungal drugs.

Stylianou M, Kulesskiy E, Lopes JP, Granlund M, Wennerberg K, Urban CF.

Antimicrob Agents Chemother. 2014;58(2):1055-62. doi: 10.1128/AAC.01087-13. Epub 2013 Nov 25.

12.

Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.

Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, Almusa H, Bespalov MM, Ellonen P, Elonen E, Gjertsen BT, Karjalainen R, Kulesskiy E, Lagström S, Lehto A, Lepistö M, Lundán T, Majumder MM, Marti JM, Mattila P, Murumägi A, Mustjoki S, Palva A, Parsons A, Pirttinen T, Rämet ME, Suvela M, Turunen L, Västrik I, Wolf M, Knowles J, Aittokallio T, Heckman CA, Porkka K, Kallioniemi O, Wennerberg K.

Cancer Discov. 2013 Dec;3(12):1416-29. doi: 10.1158/2159-8290.CD-13-0350. Epub 2013 Sep 20.

13.

Transmembrane prostatic acid phosphatase (TMPAP) interacts with snapin and deficient mice develop prostate adenocarcinoma.

Quintero IB, Herrala AM, Araujo CL, Pulkka AE, Hautaniemi S, Ovaska K, Pryazhnikov E, Kulesskiy E, Ruuth MK, Soini Y, Sormunen RT, Khirug L, Vihko PT.

PLoS One. 2013 Sep 10;8(9):e73072. doi: 10.1371/journal.pone.0073072. eCollection 2013.

14.

Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin.

Bespalov MM, Sidorova YA, Tumova S, Ahonen-Bishopp A, Magalhães AC, Kulesskiy E, Paveliev M, Rivera C, Rauvala H, Saarma M.

J Cell Biol. 2011 Jan 10;192(1):153-69. doi: 10.1083/jcb.201009136. Epub 2011 Jan 3.

15.

N-syndecan deficiency impairs neural migration in brain.

Hienola A, Tumova S, Kulesskiy E, Rauvala H.

J Cell Biol. 2006 Aug 14;174(4):569-80.

16.

Expression of the recombinant antibacterial peptide sarcotoxin IA in Escherichia coli cells.

Skosyrev VS, Kulesskiy EA, Yakhnin AV, Temirov YV, Vinokurov LM.

Protein Expr Purif. 2003 Apr;28(2):350-6.

PMID:
12699700

Supplemental Content

Loading ...
Support Center